The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRadboud University Medical Center

About this trial

The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance.

Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group.

Other tasks include:

* filling in quality of life (QOL) questionnaires at every time point; * participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional); * collecting blood at the follow-up time points for our secondary endpoint (optional).

Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.

Eligibility criteria

Qualifiers

Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment

Treated with curative intent and started follow-up care

All adjuvant treatments are permitted as co-intervention during follow-up care

Age 18 years or older

Disqualifiers

Life expectancy shorter than 6 months at the end of curative intent treatment

Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up)

Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results.

Trial design

Treatments tested in this trial

  • 18F FDG PET/CT
  • CT scan

Treatment groups

690 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Radboud University Medical Center

Lead sponsor

Amsterdam UMC, location VUmc

Collaborator

Streekziekenhuis Koningin Beatrix

Collaborator

Canisius-Wilhelmina Hospital

Collaborator

Diakonessenhuis, Utrecht

Collaborator

Dijklander Ziekenhuis

Collaborator

Deventer Ziekenhuis

Collaborator

Elisabeth-TweeSteden Ziekenhuis

Collaborator

Gelre Hospitals

Collaborator

Groene Hart Ziekenhuis

Collaborator

HagaZiekenhuis

Collaborator

Martini Hospital Groningen

Collaborator

Medisch Spectrum Twente

Collaborator

St. Antonius Hospital

Collaborator

Franciscus &Vlietland

Collaborator

Tjongerschans

Collaborator

Maasstadziekenhuis

Collaborator

Gelderse Vallei Hospital

Collaborator

Bravis Hospital

Collaborator

Tergooi Hospital

Collaborator

Treant Zorggroep

Collaborator

Amphia Hospital

Collaborator

UMC Utrecht

Collaborator

OLVG

Collaborator

Haaglanden Medical Centre

Collaborator

Antoni van Leeuwenhoek Hospital

Collaborator